Annals of Surgical Oncology 2018 March [Epub ahead of print] [Link] Takamori S et. al. Abstract BACKGROUND: Malignant pleural mesothelioma (MPM), a devastating neoplasm, is traditionally considered to be resistant to antitumor therapy. Identification of clinical prognostic indicators is therefore needed. Although the C-reactive protein/albumin ratio (CAR) has been used to predict the prognosis of…

Read More

In Vivo 2018 March [Link] Otoshi T, Kataoka Y, Kaku S, Iki R, Hirabayashi M Abstract AIM: The aim of the present study was to assess the prognostic utility of the pretreatment blood neutrophil-to-lymphocyte ratio (NLR) and the C-reactive protein-to-albumin ratio (CAR) in patients with inoperable malignant pleural mesothelioma (MPM). MATERIALS AND METHODS: The medical…

Read More

BMJ Open Respiratory Research 2018 January [Link] Kidd AC, McGettrick M, Tsim S, Halligan DL, Bylesjo M, Blyth KG Abstract INTRODUCTION: Accurate prognostication is difficult in malignant pleural mesothelioma (MPM). We developed a set of robust computational models to quantify the prognostic value of routinely available clinical data, which form the basis of published MPM…

Read More

The Clinical Respiratory Journal 2018 February 9 [Epub ahead of print] [Link] Abdel-Rahman O Abstract BACKGROUND: Malignant mesothelioma is an aggressive malignancy that is predisposed to through asbestos exposure. Little is known about the extent to which asbestos use ban has affected global trends in malignant mesothelioma. The current study investigated recent global mortality trends…

Read More

Respiration, International Review of Thoracic Diseases 2018 February 8 [Epub ahead of print] [Link] Carioli G, Bonifazi M, Rossi M, Zambelli A, Franchi M, Zocchetti C, Gasparini S, Corrao G, La Vecchia C, Negri E Abstract BACKGROUND: Pleural mesothelioma (PM) is a rare, highly lethal tumor. A definite consensus on its management has yet to…

Read More

PLoS One 2018 February 5 [Link] Stewart SA, Clive AO, Maskell NA, Penz E Abstract BACKGROUND: The SMART trial is a UK-based, multicentre RCT comparing prophylactic radiotherapy and symptom-based (deferred) radiotherapy in 203 patients with Malignant Pleural Mesothelioma who had undergone large bore pleural interventions. Using costs and quality of life data collected alongside the…

Read More

Journal of Thoracic Oncology 2018 January 10 [Epub ahead of print] [Link] Ferrara R, Mezquita L, Besse B Abstract The treatment paradigm of non-small cell lung cancer (NSCLC) underwent a major revolution during the course of 2017. Immune checkpoint inhibitors (ICIs) brought remarkable improvements in response and overall survival (OS) both in unselected pretreated patients…

Read More

Modern Pathology 2018 January 12 [Epub ahead of print] [Link] Rosen LE et.al. Abstract A recently described nuclear grading system predicted survival in patients with epithelioid malignant pleural mesothelioma. The current study was undertaken to validate the grading system and to identify additional prognostic factors. We analyzed cases of epithelioid malignant pleural mesothelioma from 17…

Read More

The Annals of Thoracic Surgery 2017 December [Epub ahead of print] [Link] Saddoughi SA, Abdelsattar ZM, Blackmon SH Abstract BACKGROUND: Malignant pleural mesothelioma (MPM) remains an aggressive malignancy that is difficult to cure. However, the treatment paradigm of MPM has evolved, and the national practice patterns are unknown. This study examined the national trends in…

Read More